We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




New Immunoassay Module Launched Doubling Immunochemistry Tests

By LabMedica International staff writers
Posted on 03 Aug 2016
As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, a new immunoassay module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel.

The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing and is now available for countries accepting the Conformité Européene (CE) Mark.

The cobas e 801 module (Roche Diagnostics, Basel, Switzerland) almost doubles the currently available immunochemistry testing capacity on the same footprint. More...
The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.

The cobas e 801 module is the newest member of the cobas 8000 modular analyzer series. It offers more than 100 immunoassays, across a wide range of disease areas. Up to four cobas e 801 modules can be configured in series, delivering up to 1,200 tests per hour across up to 192 reagent positions. The possible turn-around times for routine and emergency samples are the lowest available on the central laboratory market, with 18 minutes for routine and nine minutes for emergency tests, for instance with cardiac markers.

The small sample volumes required for testing are especially beneficial for critical patients, such as neonates and oncology patients. The cobas e 801 module uses the well-established Elecsys technology. The cobas e 801 allows for continuous loading of reagents and consumables and has a high uptime while requiring less hands-on time. Roland Diggelmann, MBA, the CEO Roche Diagnostics, said, “Today, laboratories need to deliver more diagnostic tests than ever before, while in many cases their resources are constrained. The cobas e 801 module is an important part of Roche’s connected laboratory solutions that allows laboratories to test efficiently and to sustainably grow their testing capacity.”

Related Links:
Roche Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.